Marina Biotech announces first human use of its proprietary delivery technology
BOTHELL, WA--(Marketwire - September 22, 2010) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNA-based drug discovery and development company, today announced that the first patient has received a novel cancer therapeutic candidate formulated in the Company's proprietary SMARTICLES(R) delivery technology. ProNAi Therapeutics Inc., a privately held biopharmaceutical company and licensee of the SMARTICLES technology, dosed their first patient in a Phase I clinical study of PNT2258 in patients with advanced solid tumors. PNT2258 is an oligonucleotide therapeutic encapsulated within a SMARTICLES formulation. The SMARTICLES delivery technology was developed by Novosom AG and acquired by Marina Biotech in July 2010. The SMARTICLES delivery technology is part of a broad and comprehensive patent estate surrounding amphoteric liposomal delivery now owned by Marina Biotech.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.